|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prepaid expenses and other | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill and other intangibles, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets, Total | ||||||||||||||||||||
| Liabilities and Shareholders’ Deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Current portion of long-term obligations and other short-term borrowings | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Liabilities related to assets held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term obligations, less current portion | ||||||||||||||||||||
| Deferred income taxes and other liabilities | ||||||||||||||||||||
| Shareholders’ deficit: | ||||||||||||||||||||
| Preferred shares, without par value: | ||||||||||||||||||||
| Authorized—500 thousand shares, Issued—none | ||||||||||||||||||||
| Common shares, without par value: | ||||||||||||||||||||
| Authorized—755 million shares, Issued— 271 million shares at June 30, 2026 and 2025 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Common shares in treasury, at cost: 38 million shares and 32 million shares at June 30, 2026 and 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Cardinal Health, Inc. shareholders' deficit | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders’ deficit | ||||||||||||||||||||
| Total liabilities and shareholders’ deficit | ||||||||||||||||||||
| Preferred shares, authorized | ||||||||||||||||||||
| Preferred shares, issued | ||||||||||||||||||||
| Common shares, authorized | ||||||||||||||||||||
| Common shares, issued | ||||||||||||||||||||
| Common shares in treasury |
Loading...
